Previous 10 | Next 10 |
home / stock / esaly / esaly news
Galapagos is in the midst of a transformation process that is expected to result in a completely different company by 2023. Galapagos has over $5.5 billion in cash, an approved drug and a broad pipeline with a market capitalization of only $3.2 billion. Jyseleca is approved in Jap...
Eisai and FCNT Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia TOKYO, Nov 30, 2021 - (JCN Newswire) - Eisai Co., Ltd. and FCNT LIMITED announced today that both companies have entered into a business alliance agreement aiming ...
Eisai to Present Latest Data on Perampanel and E2730 at the 75th American Epilepsy Society Annual Meeting TOKYO, Nov 30, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will conduct a total of 42 poster presentations, including the latest data on its i...
European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) for Patients With Certain Types of Endometrial Carcinoma TOKYO and KENILWORTH, N.J., Nov 29, 2021 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MS...
European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma TOKYO and KENILWORTH, N.J., Nov 29, 2021 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (...
Eisai Receives the 'Most Liked!' IR Award at The 2021 IR Award TOKYO, Nov 18, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that it has been selected as the winner of the "Most Liked!" IR Award at the 2021 IR Award, hosted by the Japan Investor Relations Association. ...
The European Medicines Agency's ("EMA") negative trend vote on Biogen's (BIIB -1.4%) Alzheimer's therapy aducanumab won't have an impact on shares since EU approval isn't priced into share assumptions, say two Street analysts. Cowen's Phil Nadeau said the vote was "disappointing, but not surp...
Eisai: New Phase 3 Data Show Positive Correlation Between ADUHELM Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer's Disease TOKYO, Nov 12, 2021 - (JCN Newswire) - Biogen Inc. and Eisai Co., Ltd. (Tokyo, Japan) announced that data from approximatel...
Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2b Study at Clinical Trials On Alzheimer's Disease (CTAD) Conference TOKYO and CAMBRIDGE, Mass., Nov 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today results of sensitivity...
Eisai: Introduction of Plasma-based Biomarker Screening to Facilitate Identification of Subjects for Phase 3 Ahead 3-45 Trial Presented at Clinical Trials on Alzheimer's Disease (CTAD) Conference TOKYO and CAMBRIDGE, Mass., Nov 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. and B...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co. Ltd. ADR Company Name:
ESALY Stock Symbol:
OTCMKTS Market:
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities TOKYO, May 25, 2023 - (JCN Newswire) - Eisai Co., Ltd. has announced that it will grant a t...
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 TOKYO, May 24, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline durin...
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., May 16, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (b...